| Q35166807 | A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections |
| Q36882486 | Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus |
| Q36525654 | Antibiotics for treatment of resistant gram-positive coccal infections |
| Q37465197 | Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management |
| Q36482313 | Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia |
| Q27006038 | Daptomycin in paediatrics: current knowledge and the need for future research |
| Q40189196 | Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria |
| Q55114463 | Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. |
| Q36003721 | Daptomycin: a cyclic lipopeptide antimicrobial agent |
| Q36972980 | Daptomycin: a review 4 years after first approval |
| Q36718474 | Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections |
| Q28488311 | In vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pH |
| Q46471549 | In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections |
| Q39686976 | Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms |
| Q37600385 | Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria |
| Q36162339 | Oritavancin: a new avenue for resistant Gram-positive bacteria |
| Q45258208 | Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis |
| Q40174540 | Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area |
| Q44958662 | The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus |
| Q33233009 | Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin |
| Q34228237 | Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm |